Abstracts Archive - Page 2 of 2607 - ACR Meeting Abstracts

Abstract Number: LB08 • ACR Convergence 2025
Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study
Philip Mease¹, Frank Behrens², Alan Kivitz³, Edit Drescher⁴, Piotr Klimiuk⁵, Howard Sofen⁶, Nehad Soloman⁷, Shephard Mpofu⁸, Fredrik Frejd⁹ and Peter Taylor¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington, ²Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ³Altoona Arthritis and Osteoporosis Center, Altoona Center for Clinical Research, Duncansville, Pennsylvania, ⁴Vital Medical Center Rheumatology, Veszprém, Hungary, ⁵Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland, ⁶Department of Medicine/Dermatology, David Geffen UCLA School of Medicine, Los Angeles, California, ⁷Midwestern University Arizona College of Osteopathic Medicine and Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona, ⁸ACELYRIN, INC., Agoura Hills, California, ⁹Affibody Medical AB, Solna, Sweden, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: PsA is a chronic, systemic, inflammatory musculoskeletal disease in which dysregulated IL-17A activity plays a pivotal role in disease pathogenesis. Izokibep (IZO) is an…
Abstract Number: LB11 • ACR Convergence 2025
Efficacy and Safety of Telitacicept in Patients with Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study
Dong Xu¹, Shangzhu Zhang¹, Lin Qiao¹, Li Zhang¹, Wenxiang Wang², Lin Li², Binghua Xiao², Jing Zhang², Qing Zuraw³, Jianmin Fang² and Xiaofeng Zeng¹, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China (People's Republic), ²RemeGen Co., Ltd., Rheumatology, Yantai, China (People's Republic), ³Vor Biopharma Inc., Boston
Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease whose pathogenesis is associated with aberrant activation of B-lymphocytes. Telitacicept, a novel fusion protein, dually targets and…
Abstract Number: LB24 • ACR Convergence 2025
Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2)
Thomas Grader-Beck¹, Xavier Mariette², Stephanie Finzel³, Elena Schiopu⁴, Athena Papas⁵, Valerie Devauchelle-Pensec⁶, Thomas Dörner⁷, Monika Sopala⁸, Xiaofeng Zeng⁹, Ghaith Noaiseh¹⁰, Tsutomu Takeuchi¹¹, Uma Kumar¹², Josef Hermann¹³, Hiroki Ozawa¹⁴, Robert Fox¹⁵, Susan Zong¹⁶, Deepak Narayanswamy¹⁷, XIAOMEI LI¹⁸, Wen-Lin Luo¹⁹, Janice Woznicki²⁰, Laurie DeBonnett²¹, Xuan Zhu²⁰, Linchen He²⁰, Franziska Matzkies²², Angelika Jahreis²², Brian Porter²³, Sara McCoy²⁴, Simon Bowman²⁵ and Wolfgang Hueber²², ¹Johns Hopkins, Reisterstown, Maryland, ²Universit Paris-Saclay, Le Kremlin-Bictre, France, ³University Medical Center Freiburg, Freiburg, Germany, ⁴Medical College of Georgia at Augusta University, Martinez, Georgia, ⁵Tufts School of Dental Medicine, Boston, Massachusetts, ⁶Department of Rheumatology, Université de Bretagne Occidentale, CHU Brest, INSERM (U1227), LabEx IGO, Brest, France, ⁷Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum,, Berlin, Germany, ⁸Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁹Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ¹⁰University of Kansas Medical Center, Kansas City, Kansas, ¹¹Division of Rheumatology and Clinical Immunology, Keio University,, Tokyo, Japan, ¹²Department of Rheumatology, All India Institute of Medical Sciences,, New Delhi, India, ¹³Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz,, Graz, Austria, ¹⁴Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ¹⁵Division of Rheumatology, Scripps Memorial Hospital and Research Foundation-Ximed, La Jolla,, San Diego, California, ¹⁶Novartis Pharmaceuticals Corporation, Bridgewater Township, New Jersey, ¹⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹⁸First Affiliated Hospital of China University of Science and Technology, Hefei, China, ¹⁹Novartis Pharmaceuticals Corporation, Franklin Township, New Jersey, ²⁰Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, ²¹Novartis Pharmaceuticals Corporation, Mt Olive, New Jersey, ²²Novartis Pharma AG, Basel, Switzerland, ²³Novartis Pharmaceuticals, East Hanover, New Jersey, ²⁴University of Wisconsin, Middleton, Wisconsin, ²⁵University Hospitals Birmingham, Birmingham, United Kingdom

Background/Purpose: Sjögren's disease (SjD) is a systemic, heterogeneous, autoimmune disease with substantial disease burden, high unmet need, and no approved systemic treatments. B cell hyperactivity…
Abstract Number: LB21 • ACR Convergence 2025
IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation
Flore Castellan¹, Griffen Mustion², Mei-Kay Wong¹, Kimberly Johansson², Scott Goldberg¹, Yazan Madanat³, Namrata Chandhok⁴, Abhay Singh⁵, David Sallman⁶, Jane Churpek⁷, Curtis Lachowiez⁸, Jennifer Yannucci⁹, Luke Fletcher¹⁰, Matthew Schwede¹¹, Amber Afzal², Yael Kusne¹², Alejandro Marinos¹³, Alexander Coltoff¹⁴, Rickey Myhand¹⁵, Kiran Vij², Rosalyn Marar¹⁶, Hannah Mitchell², Maria Stoentcheva², Giulia Petrone², Kyra Ddungu², Hannah Hartman², Ryan Monahan², Karen Vandervort², Jie Liu², John Cole², Tibor Kovacsovics¹⁷, Hetty Carraway¹⁸, Tian Zhang¹⁹, Stephen Chung³, Geoffrey Uy², Eytan Stein²⁰, Devendra Hiwase²¹, Matthew Walter², Mrinal Patnaik¹⁶, Kelly Bolton²² and David Beck¹, ¹New York University School of Medicine, New York, New York, ²Washington University School of Medicine, Saint Louis, Missouri, ³UT Southwestern Medical Center, Dallas, Texas, ⁴University Miami Miller School of Medicine, Miami, Florida, ⁵Cleveland Clinic, Cleveland, Ohio, ⁶Moffitt Cancer Center, Tampa, Florida, ⁷University of Wisconsin School of Medicine, Madison, Wisconsin, ⁸Oregon Health & Science University, Portland, Oregon, ⁹Low Country Cancer Care, Savannah, Georgia, ¹⁰Willamette Valley Cancer Institute and Research Center, EUgene, Oregon, ¹¹Swedish Health Services, Seattle, Washington, ¹²Mayo Clinic, Phoenix, Arizona, ¹³UTSouthwestern Medical Center, Dallas, Texas, ¹⁴Medical University of South Carolina, Charleston, South Carolina, ¹⁵CovenantOntology & Hematology, Frankfort, Kentucky, ¹⁶Mayo Clinic, Rochester, Minnesota, ¹⁷City of Hope, Goodyear, Arizona, ¹⁸Case Western Reserve University, Cleveland, Ohio, ¹⁹Stanford Medicine, Stanford, California, ²⁰Memorial Sloan Kettering Cancer Center, New York, New York, ²¹Adelaide Medical School, Adelaide, South Australia, Australia, ²²Washington University School of Medicine, Saint Louis, Minnesota
Background/Purpose: Recently, somatic mutations in hematopoietic stem and progenitor cells (HSPCs) have been proposed as a novel mechanism driving systemic inflammation. UBA1 somatic variants in…
Abstract Number: LB14 • ACR Convergence 2025
Promising Early Outcomes With BMS-986353, a CD19-directed Chimeric Antigen Receptor T Cell Therapy in Severe Refractory Idiopathic Inflammatory Myopathies: Safety and Efficacy Findings From the Ongoing Phase 1 Trial
Rohit Aggarwal¹, David Korman², Margrit Wiesendanger³, Vikas Majithia⁴, Ellen De Langhe⁵, Marc Schmalzing⁶, Melissa Griffith⁷, Philipp Koehler⁸, Joanna Schiller⁸, Dimitrios Mougiakakos⁹, Mohamad Cherry¹⁰, Richard Nash¹¹, Jacques Azzi¹², Ernesto Ayala⁴, Peter Vandenberghe⁵, Max Topp⁶, Jonathan Gutman⁷, Eugen Feist¹³, Alisha Desai¹⁴, Alexis Melton¹⁴, Alice Wozniak¹⁴, San-San Ou¹⁴, Melissa Harnois¹⁴, Jerill Thorpe¹⁴, Praneeth Jarugula¹⁴, Takafumi Ide¹⁴, Ashley Koegel¹⁴ and Neil Kramer¹⁵, ¹University of Pittsburgh, Pittsburgh, Pennsylvania, ²Mountain Rheumatology, HCA HealthONE, Denver, Colorado, ³Icahn School of Medicine at Mount Sinai, New York, New York, ⁴Mayo Clinic Hospital, Jacksonville, Florida, ⁵University Hospitals Leuven, Leuven, Belgium, ⁶University Hospital Würzburg, Würzburg, Germany, ⁷University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Division of Clinical Immunology and Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, Cologne, Germany, ⁹University Hospital Magdeburg, Magdeburg, Germany, ¹⁰Atlantic Health System, Morristown, New Jersey, ¹¹HealthOne Cares and Colorado Blood Cancer Institute, Denver, Colorado, ¹²Icahn School of Medicine at Mount Sinai Hospital, New York, New York, ¹³Helios Vogelsang-Gommern Specialist Clinic, Gommern, Germany, ¹⁴Bristol Myers Squibb, Princeton, New Jersey, ¹⁵Overlook Medical Center and Atlantic Medical Group, Atlantic Health System, Morristown, New Jersey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are systemic autoimmune diseases affecting muscles, skin, lungs, joints, and several other organs; many patients are refractory to available therapy,…
Abstract Number: LB04 • ACR Convergence 2025
Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases
Huihua Ding¹, Wensi Li², Yiwen Shen³, Chunyan Zhang⁴, Yan Ye³, Ran Wang³, Shaoying Yang³, Chunmei Wu³, Dai Dai³, Chengxiao Zheng², Yuan Qian², Xiaobing Luo⁵, Thule Trinh⁵, Judy Zhu², Jiaqi Huang⁵, Yong Hao³, Xiaoying Yao³, Zhenfen Ling⁶, Yihong Yao⁵ and Nan Shen¹, ¹Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ²Shanghai AbelZeta Ltd., Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China, ⁵AbelZeta Inc., Rockville, ⁶Shanghai General Hospital, Shanghai, China (People's Republic)
Background/Purpose: Refractory autoimmune diseases with progressive organ damage remain a major unmet medical need. C-CAR168 is an autologous anti-CD20/BCMA bispecific CAR-T therapy designed to simultaneously…
Abstract Number: LB22 • ACR Convergence 2025
Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency
Andreas Reiff¹, Tadej Avcin², Bernd Jilma³, Peter Korosec⁴, Matthias Weiss-Tessbach³, Christian Schoergenhofer³, Masa Bizjak⁵, Barbara Jenko Bizjan⁶, Barbara Cugalj Kern⁵, Kim Simpfendorfer⁷, Christian Lood⁸, Tyler Artner⁹, Angelene Prasanna¹, Ken Olivier¹, Ghazaleh Gouya¹, Ralph Lambalot⁹, Abdul Hakkim¹ and Tobias Fuchs¹, ¹Neutrolis, Cambridge, Massachusetts, ²University Medical Centre Ljubljana, Ljubljana, Slovenia, ³Medical University of Vienna, Vienna, Austria, ⁴University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, ⁵University Medical Center Ljubljana, Ljubljana, Slovenia, ⁶University of Ljubljana, Ljubljana, Slovenia, ⁷Feinstein Institutes for Medical Research, Manhasset, New York, ⁸University of Washington, Seattle, Washington, ⁹Neutrolis, Cambridge
Background/Purpose: Excessive formation and impaired clearance of Neutrophil Extracellular Traps (NETs) have been linked to autoimmune and inflammatory diseases, notably systemic lupus erythematosus (SLE). DNASE1-like…
Abstract Number: LB16 • ACR Convergence 2025
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
David Silverman¹, Timothy Barnes², Nnaemeka Odo², Jared Silver³, Lisa Le², Amy Edgecomb⁴ and Hitesh Patel⁵, ¹Rheumatology Department, Kaiser Permanente Colorado Medical Group, Denver, Colorado, ²Value and Evidence Solutions, Optum Life Sciences, Eden Prairie, Minnesota, ³Clinical Development, Amgen, Thousand Oaks, California, ⁴Anti-infectives and Respiratory, GSK, Philadelphia, Pennsylvania, ⁵US Medical Affairs, GSK, Durham, North Carolina
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…
Abstract Number: LB12 • ACR Convergence 2025
Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis (OA): 3-Month Positive Outcomes and Identification of Responder Population (NCT06233474)
Philip Conaghan¹, Bernt Husøy², Cecilie Rovsing³, Sidsel L Boll⁴, Liliana Groppa⁵, Amir Oron⁶, Asger Bihlet⁷, Ali Mobasheri⁸, Tobias Winkler⁹, Dror Mevorach¹⁰, Einat Galamidi¹¹, Lital Weinfeld-Bergman¹², Lior Binder¹² and Oren Hershkovitz¹¹, ¹University of Leeds, Leeds, United Kingdom, ²Sanos Clinic, Herlev, Denmark, ³Sanos Clinic, Gandrup, Denmark, ⁴Sanos Clinic, Vejle, Denmark, ⁵T. Mosneaga Republican Clinical Hospital, Chisinau, Moldova, ⁶Kaplan MC, Rehovot, Israel, ⁷NBCD A/S, Soeborg, Denmark, ⁸University of Oulu, Oulu, Finland, ⁹Charité - Universitätsmedizin Berlin, Berlin, Germany, ¹⁰Hadassah-University Hospital, Jerusalem, Israel, ¹¹Enlivex Therapeutics, Ness Ziona, Israel, ¹²Enlivex Therapeutics, Nes Ziona, Israel
Background/Purpose: OA is a prevalent disabling disease growing globally due to aging populations and rising obesity. In primary OA, the effects of joint tissue damage accumulate with age,…
Abstract Number: 2283 • ACR Convergence 2025
Arrhythmia Risk in Diabetic Rheumatoid Arthritis Patients: Comparative Analysis of IL-6 Inhibitors versus TNF-α Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure², Gurjot Singh³, Kim Nguyen³, Nirys Mateo Faxas⁴, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: Background: Both rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) are independently associated with increased cardiovascular risk, including cardiac arrhythmias. The impact of…
Abstract Number: 2287 • ACR Convergence 2025
Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
yinan huang¹ and Sandeep Agarwal², ¹Department of Pharmacy Administration, University of Mississippi, Oxford, MS, US, MS, ²Baylor College of Medicine, Houston
Background/Purpose: Interpretable machine learning (ML) method can identify factors associated with biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) nonadherence and nonpersistence for rheumatoid…
Abstract Number: 2285 • ACR Convergence 2025
Synovium-on-a-chip – Development of a Humanized Rheumatoid Arthritis Model that Mimics Disease and Patient Biological Heterogeneity
Theresa Wampler Muskardin¹, Ruiqi Chen², Yeji Lee³, Azka Ali³, Andrra Nimoni³, Christele Felix³, Hattie Heiland³, Romy Kallas³, Daniel Ramirez⁴, David Mayman³, Timothy Niewold⁵ and Weiqiang Chen⁶, ¹Hospital for Special Surgery and Weill Cornell Medicine, New York, NY, ²New York University - Tandon School of Engineering, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, New York, ⁶New York University, Tandon School of Engineering, New York, NY
Background/Purpose: In rheumatoid arthritis (RA), reasons for treatment resistance and alternate strategies that would be more effective in treatment-resistant patients remain unknown. Accurate methodology to…
Abstract Number: 2284 • ACR Convergence 2025
Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure¹, Gurjot Singh², Kim Nguyen², Nirys Mateo Faxas³, Nicole Tejeda⁴, Kimberly Ramirez Bonetti⁵ and Erick Perez Mejias⁴, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, ³Independent Author, Santo Domingo, Dominican Republic, ⁴Independent Author, Cincinnati, ⁵Independent Author, cincinnati, OH
Background/Purpose: Patients with rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) face increased cardiovascular risk. Different biologic disease-modifying antirheumatic drugs (bDMARDs) may have varying…
Abstract Number: 2282 • ACR Convergence 2025
Effect of Online Continuing Education on Advancing Care for Rheumatoid Arthritis: A Real-World Outcome Analysis
Nimish Mehta¹, Katie Lucero², Freddy Green³ and Karen Badal⁴, ¹Medscape, Three Bridges, NJ, ²Medscape, Newark, ³Medscape, London, United Kingdom, ⁴Medscape, New York, NY
Background/Purpose: In recent years, an increasing number of cytokines and their function in the pathophysiology of immunologic conditions have been identified, leading to the development…
Abstract Number: 2281 • ACR Convergence 2025
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Final Results from the CLOSE-UP Post-Marketing Observational Study
Louis Bessette¹, Andrew Chow², Raman Rai³, Hugues Allard-Chamard⁴, Pauline Boulos⁵, Guylaine Roy⁶ and Dalinda Liazoghli⁶, ¹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ²Credit Valley Rheumatology, Mississauga, McMaster University, Hamilton, University of Toronto, Toronto, ON, Canada, ³Drs. Rai & Sekhon Medicine Professional Corporation, Brampton, ON, Canada, ⁴Université de Sherbrooke, Sherbrooke, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶AbbVie Corporation, Saint-Laurent, QC, Canada
Background/Purpose: Upadacitinib (UPA) is an oral, selective Janus kinase (JAK)-inhibitor proven effective and well-tolerated in patients with rheumatoid arthritis (RA) in 6 randomized clinical trials.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].